Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
A comprehensive review of cancer drug-induced cardiotoxicity in blood cancer patients: Current perspectives and therapeutic strategies.
Curr. Treat. Options Oncol. 25, 465-495 (2024)
Cardiotoxicity has emerged as a serious outcome catalyzed by various therapeutic targets in the field of cancer treatment, which includes chemotherapy, radiation, and targeted therapies. The growing significance of cancer drug-induced cardiotoxicity (CDIC) and radiation-induced cardiotoxicity (CRIC) necessitates immediate attention. This article intricately unveils how cancer treatments cause cardiotoxicity, which is exacerbated by patient-specific risks. In particular, drugs like anthracyclines, alkylating agents, and tyrosine kinase inhibitors pose a risk, along with factors such as hypertension and diabetes. Mechanistic insights into oxidative stress and topoisomerase-II-B inhibition are crucial, while cardiac biomarkers show early damage. Timely intervention and prompt treatment, especially with specific agents like dexrazoxane and beta-blockers, are pivotal in the proactive management of CDIC.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Blood Cancer ; Cardiotoxicity ; Cardiovascular Disease ; Immunotherapy ; Therapeutics; Chronic Myeloid-leukemia; Anthracycline-associated Cardiotoxicity; Chronic Lymphocytic-leukemia; Renal-cell Carcinoma; Long-term Survivors; Cardiovascular Toxicity; Hodgkin Lymphoma; Heart-disease; Doxorubicin Cardiotoxicity; Cardiac-disease
ISSN (print) / ISBN
1527-2729
e-ISSN
1534-6277
Quellenangaben
Volume: 25,
Issue: 4,
Pages: 465-495
Publisher
Springer
Publishing Place
One New York Plaza, Suite 4600, New York, Ny, United States
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Lung Health and Immunity (LHI)